Obesity Market Growing

According to the data provided by the Decision Resources Research company, the market of anti-obesity medications and therapies is likely to grow five times by the year 2016.
The company’s analysts anticipate that the market worth approximately $478 million 2 years ago will reach almost $3 billion within the next 8 years in the USA and Western Europe.

The report projects that such an incredible market growth will be mostly driven by the expected launch of a number of therapies such as Lorcaserin manufactured by Arena Pharmaceuticals and a combination of Pramlintide and Leptin delivered by Amylin. However, the report also predicts that the cautious attitude of the FDA towards the newly developed anti-obesity medications can significantly slow down the projected growth rates. The authors of the report base their opinion on the case of Rimonabant (Acomplia) manufactured by Sanofi-Aventis and the safety concerns over similar drugs in the class such as tranabant.